While clinical disease stages remained largely unchanged in the 2024 update of the Alzheimer disease (AD) criteria, tau–positron emission tomography (PET) was introduced as a core biomarker and its spatial extent was incorporated into the revised biological stages of the disease. The gene discussed is MAPT; the disease is Alzheimer disease.